These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19043603)

  • 1. PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.
    Veliceasa D; Schulze-Hoëpfner FT; Volpert OV
    PPAR Res; 2008; 2008():945275. PubMed ID: 19043603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARgamma as a therapeutic target for tumor angiogenesis and metastasis.
    Panigrahy D; Huang S; Kieran MW; Kaipainen A
    Cancer Biol Ther; 2005 Jul; 4(7):687-93. PubMed ID: 16082179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New target genes for the peroxisome proliferator-activated receptor-γ (PPARγ) antitumour activity: Perspectives from the insulin receptor.
    Foti DP; Paonessa F; Chiefari E; Brunetti A
    PPAR Res; 2009; 2009():571365. PubMed ID: 19587804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies.
    Augimeri G; Giordano C; Gelsomino L; Plastina P; Barone I; Catalano S; Andò S; Bonofiglio D
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32937951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARγ signaling and emerging opportunities for improved therapeutics.
    Wang S; Dougherty EJ; Danner RL
    Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARγ Agonists in Combination Cancer Therapies.
    Mrowka P; Glodkowska-Mrowka E
    Curr Cancer Drug Targets; 2020; 20(3):197-215. PubMed ID: 31814555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine.
    Cataldi S; Costa V; Ciccodicola A; Aprile M
    Curr Diab Rep; 2021 Apr; 21(6):18. PubMed ID: 33866450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
    Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
    Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
    Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
    Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
    Landreth G
    Curr Alzheimer Res; 2007 Apr; 4(2):159-64. PubMed ID: 17430241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-highlighting the action of PPARγ in treating metabolic diseases.
    Choi SH; Chung SS; Park KS
    F1000Res; 2018; 7():. PubMed ID: 30079233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
    Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates.
    Mal S; Dwivedi AR; Kumar V; Kumar N; Kumar B; Kumar V
    Curr Med Chem; 2021; 28(16):3193-3215. PubMed ID: 32674727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation.
    Zingarelli B; Cook JA
    Shock; 2005 May; 23(5):393-9. PubMed ID: 15834303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG; Hele DJ; Birrell MA
    Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARgamma and its ligands: therapeutic implications in cardiovascular disease.
    Villacorta L; Schopfer FJ; Zhang J; Freeman BA; Chen YE
    Clin Sci (Lond); 2009 Feb; 116(3):205-18. PubMed ID: 19118492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.